Cooper Companies (The) (COO)
Health Care · Medical devices - ophthalmology and eye care · NASDAQ
A global medical device leader operating at the intersection of vision care and women's health through its CooperVision and CooperSurgical divisions.
What Cooper Companies (The) does
Cooper Companies is a global healthcare company that manufactures and markets contact lenses, lens care products, intraocular lenses, and related devices for the eye care market. The company operates through two main segments: CooperVision, which produces contact lenses and lens care solutions, and CooperSurgical, which manufactures surgical devices and fertility products. Cooper serves customers worldwide including ophthalmologists, optometrists, and fertility clinics through direct and distribution channels.
Themes: Eye care / ophthalmology, Contact lenses, Surgical ophthalmic devices, Intraocular lenses (IOLs), Fertility / reproductive health, Global healthcare, Vision correction
Fundamentals
- Price$76.22 as of 2026-08-21 close
- Market cap$14.9B as of 2026-08-21
- 1-year return+4.4% 2025-08-21 close $73.04 → 2026-08-21 close $76.22
- P/E63.74 as of 2026-08-24
- Net margin+5.6% as of 2026-08-24
- Gross margin+65.5% as of 2026-08-24
- ROE+2.8% as of 2026-08-24
- Debt / equity0.30 as of 2026-08-24
- Revenue growth (YoY)+6.1% as of 2026-08-24
- Revenue CAGR (3y)+7.3% SEC XBRL
- Beta0.81 as of 2026-08-24
- Last reported earnings2026-06-04 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.0%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How COO compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldbottom 10% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
COO is not currently in any published Top 10 list. Its scores are below.
Long-term score
46.6 #630 of 987 scored · #38 of 57 in Health Care
Capital return 71st (consecutive years of dividend increases 5 years) and financial health 65th (debt to equity 0.3, free cash flow margin 13.5%); weakest is profitability (23rd, return on equity 2.8%, operating margin 11.8%).
Short-term score
59.1 #261 of 1,704 scored · #56 of 240 in Health Care
Volume and participation 68th: it gapped 5.2% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; trend 66th: the price is 8% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; weakest is catalysts 47th: open-market insider buys in 90 days 1, the analyst consensus rating is unchanged since the prior reading.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which COO reported a dividend payment is FY2023, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2023 ratio would not describe COO today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2023) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How Cooper Companies (The) looks technically
Cooper Companies (The) (COO) is trading 3.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 80 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 61, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 9 trading days ago. It is 15.2% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 3.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +3.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $71.82 | $71.82 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $73.38 | $73.38 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 69.6. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 80 trading days ago — a "death cross", a bearish long-term signal | 80 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 3.9% above | +3.9% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control | 28.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 61, neither overbought (above 70) nor oversold (below 30) | 60.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($72.65 to $78.11) — its "stochastic" reading is 65 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 65.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $89.83 | $89.83 |
|---|---|---|
| From the 52-week high | it is 15.2% below its 52-week high (its highest price of the past year) | -15.2% |
| Above the 52-week low | it is 29.4% above its 52-week low (its lowest price of the past year) | +29.4% |
| Below the 52-week high | it is 15.2% below its highest point of the past year | 15.2% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day high about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $115.90 (set on 2021-09-03) | $115.90 |
| Given back of the 52-week move | over the past year its closes ranged ($58.98 to $84.32), and it has recovered well over two thirds of its fall from last year’s high — 68% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $74.64 to $75.45. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 68.0% |
| From the all-time high | it is 34.2% below its all-time high | -34.2% |
| Nearest price level | it is trading 0.7% below a resistance level at $76.78 — a price it turned at three times since 2025-03-13, most recently on 2025-10-20. Since 2024-08-21 it has 8 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.7% |
| All-time low | its lowest closing price on record is $2.54 (set on 2008-11-20) | $2.54 |
| Above the all-time low | it is 2897.8% above its all-time low | +2,898% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 40th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.59 between its high and its low — about 2.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.59 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $71.02 and $78.41 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $71.02 – $74.72 – $78.41 |
| Typical daily range (% of price) | its price moves about 2.1% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.1% |
| Stretch from the 200-day average | it is trading 1.8 daily ranges above its 200-day average price (3.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.85× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.4% since the prior reading | +0.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | +0.0% |
|---|---|---|
| Open gap | it gapped 5.2% above the previous close 50 sessions ago and has not traded back through the level it left behind at 62.02 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +5.2% |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 5.0 percentage points (the stock gained 7.3% while the market gained 2.3%) | +5.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 18.2 percentage points (the stock gained 21.3% while the market gained 3.1%) | +18.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 20.4 percentage points (the stock lost 9.3% while the market gained 11.1%) | -20.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 16.1 percentage points (the stock gained 4.4% while the market gained 20.5%) | -16.1% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.6% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.8% of the share price. | +9.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $71.62 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +6.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-06-04 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $70.60 — a volume-weighted average of daily closes over 52 sessions, not a true tick-by-tick VWAP. | +8.0% |
Price levels it has turned at before
COO last closed at $76.22 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $76.78 | Resistance | 0.7% above the last close | turned there three times · 2025-03-13 to 2025-10-20 |
| $74.80 | Support | 1.9% below the last close | turned there four times · 2025-07-25 to 2026-07-02 |
| $78.82 | Resistance | 3.4% above the last close | turned there three times · 2025-05-14 to 2026-02-03 |
| $73.15 | Support | 4.0% below the last close | turned there four times · 2025-06-10 to 2026-07-17 |
| $80.19 | Resistance | 5.2% above the last close | turned there twice · 2026-01-05 to 2026-01-14 |
| $71.16 | Support | 6.6% below the last close | turned there twice · 2025-07-21 to 2025-10-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $69.60.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · lagging the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$81.50 range $66.00 – $92.00; median $85.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for COO
- Consensus EPS estimate$1.12 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant exposure to foreign exchange fluctuations and currency translation impacts on reported revenues and earnings, particularly given substantial international operations","Recent elevated litigation liabilities and accrued contingent liabilities creating financial uncertainty and potential material cash outflows","Intense competition in contact lens and ophthalmic device markets from larger diversified medical device companies that could pressure pricing and market share"]
What changed in the latest 10-Q
AI-assisted comparison of COO's 10-Q filed 2026-06-05 against the prior one filed 2026-03-06.
Management's Discussion & Analysis (MD&A)
- Added:
- New Item 1. Legal Proceedings section added in newer filing describing CooperSurgical's December 2023 voluntary recall of LifeGlobal embryo culture media and related litigation developments as of June 5, 2026, including more than 140 lawsuits filed, over 1,500 claimants, and a net $271.6 million accrual recorded ($324.1 million litigation liability offset by $52.5 million insurance recoveries) recorded in SG&A expenses (filed 2026-06-05)
- New language in newer Item 2 regarding legal accruals requiring significant judgment with reference to Note 9 Contingencies and Commitments (filed 2026-06-05)
- Removed:
- Share Repurchase section removed from newer filing that was present in older filing discussing September 2025 authorization increase to $2.0 billion and January 31, 2026 repurchase activity (filed 2026-03-06)
- Contingencies section header and related discussion removed from newer filing that appeared in older Item 2 MD&A (filed 2026-03-06)
- Estimates and Critical Accounting Policies section removed from newer filing that was in older Item 2 (filed 2026-03-06)
- Reworded:
- Foreign currency sensitivity updated from $34.9 million (January 31, 2026) to $35.5 million (April 30, 2026) with corresponding date change in measurement reference (filed 2026-06-05 vs 2026-03-06)
- Interest rate risk example reference updated from 'first quarter of fiscal 2026' to 'second quarter of fiscal 2026' (filed 2026-06-05 vs 2026-03-06)
- Disclosure controls evaluation date updated from January 31, 2026 to April 30, 2026 (filed 2026-06-05 vs 2026-03-06)
- Internal control changes reference updated from 'first quarter of fiscal 2026' to 'second quarter of fiscal 2026' (filed 2026-06-05 vs 2026-03-06)
- UK FTT legal proceedings section in Item 1 updated: 'in the process of appealing' (newer, filed 2026-06-05) versus 'intends to appeal' (older, filed 2026-03-06)
- Reference note changed from 'Note 9 – Commitments and Contingencies' (older filing) to 'Note 9. Contingencies and Commitments' (newer filing)
- Notes:
- The older filing sections on Share Repurchase, Contingencies, and Estimates may have been reorganized or moved rather than removed; comparison is limited to MD&A section structure provided
- Foreign currency and interest rate sensitivity figures represent point-in-time measurements at different quarter ends and are not necessarily comparable as changes in underlying business metrics
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for COO — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for COO from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding COO as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 26,114,371
- Reported value $1,867,177,613
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
COO had 8,344,882 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
COO had 4.28% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.4 days to cover at the same settlement.
- Reported short interest (shares) 8,344,882
- Short interest (% of shares outstanding) 4.28%
- Prior settlement (shares) 7,918,348
- Reported change 5.39%
- Days to cover (reported) 4.4
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alcon (ALC)
- Bausch + Lomb (BLCO)
- Johnson & Johnson Vision (JNJ)
- Hoya Corporation
- EssilorLuxottica
- Vitrolife
- FUJIFILM Irvine Scientific
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare COO vs…
Frequently asked questions
What does Cooper Companies (The) (COO) do?
Cooper Companies is a global healthcare company that manufactures and markets contact lenses, lens care products, intraocular lenses, and related devices for the eye care market. The company operates through two main segments: CooperVision, which produces contact lenses and lens care solutions, and CooperSurgical, which manufactures surgical devices and fertility products.
What sector is Cooper Companies (The) (COO) in?
Cooper Companies (The) (COO) is classified in the Health Care sector. Its industry is Medical devices - ophthalmology and eye care. It trades on NASDAQ.
Does COO pay a dividend?
Yes — Cooper Companies (The) (COO) pays a dividend, with an indicated yield of about 0.02% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Cooper Companies (The)'s (COO) competitors?
Notable peers of Cooper Companies (The) (COO) include Alcon, Bausch + Lomb, Johnson & Johnson Vision, Hoya Corporation and EssilorLuxottica. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in COO?
Yes — we hold 4 matched STOCK Act disclosures for COO from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Cooper Companies (The) (COO) overbought or oversold right now?
Cooper Companies (The) (COO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 61, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on COO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.